MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Medical Journal of Clinical Trials & Case Studies
ISSN: 2578-4838

# Systems of Weak Immunogenicity as Originators of Early Spread and of Incremental Tumor Cell Growth and Proliferation

**Agius Ml***

Department of Pathology, Mater Dei Hospital, Tal-Qroqq, University of Malta Medical School, Malta

***Corresponding author:** Lawrence M Agius, Department Of Pathology, Mater Dei Hospital, Tal-Qroqq, University of Malta Medical School, Msida, 27 "Ballarat" Guzeppe Caruana Street, Tal-Virtu, Rabat, Rbt09, Malta, Europe, Tel: 356-21451752; Email: lawrence.agius@um.edu.mt

**Commentary**

**Volume 5 Issue 2**

**Received Date:** February 20, 2021

**Published Date:** March 18, 2021

DOI: 10.23880/mjccs-16000283

## Abstract

Dimensions of the dynamic increments in tumor evolution indicate the inherent nature of the tumor cells as derivative biology of a weak immunogenicity and as further dominated by the acquisition of early metastatic spread potential as carcinogenesis progresses. It is in terms of incremental growth and spread of the neoplastic cells that the proliferation of such cells proves an originator of the performance profiles of network operability within systems of pronounced amplification of the weak immunogenicity as exhibited by the neoplastic cells.

**Keywords:** Immunogenicity; Tumor Cell; Proliferation; Carcinogenesis; Exhibited

## Introduction

The combination of various immunotherapeutic agents, in particular the bolus injection modules of administration of interleukin 2, has shown a therapeutic effect in a small population of metastatic renal cell carcinoma patients and patients with melanoma. As such, the realization of therapeutic effect is beset by the development of significant toxicity in these patients. Therefore, there have been several attempts at combination therapy, particularly the combination of interferon alpha with interleukin 2 with the aim of achieving synergistic action against the tumors.

The modulatory effects of a direct anti-proliferative action of interferon alpha on tumor cells are a significant facet in the overall anti-tumor strategy in melanoma and renal cell carcinoma patients. These two types of tumors, particularly melanoma, serve as important models in the outline attempts at formulating strategies against most other solid-type tumors. It is the realization of both direct and indirect actions against tumor cells that attempts at combinatory immunotherapy have been formulated for future strategy.

The number of disseminated tumor cells and their karyotypic abnormalities are similar for small and large tumors in patients and mouse models [1]. In carcinoma progression, epithelial to mesenchymal transition plays a crucial role in early steps of metastasis when cells lose cell to cell-contacts [2].

### Systems of Toxicity

The overall systems of toxicity are significant in terms of such organ systems as hepatotoxicity that often prove a limiting effect in the administration of immunotherapeutic agents to tumor patients. The systems of continuous rather than bolus administration modules may prove advantageous in terms of limiting toxicity modules, but such attempts are further compromised in terms of lack of efficacy of anti-tumor effect in the vast majority of patients with metastatic melanoma or metastatic renal cell carcinoma.

## Tumor Growth and Proliferation

In terms of realization in the control of tumor cell growth and proliferation, it is significant to consider the terms of reference in models of cancer cell biology. Natural killer cells contribute to the first line of defence agains tumor growth and metastasis spread [3]. Combination immunotherapy to such agents as chemotherapy, and in the strategic attempts of anti-tumor effect, is significant within focused attack against multiple biologic facets of tumor cell proliferation and growth and also especially in the control of metastatic biology. Incorporating immune-molecular targets into combination as well as refining the standard chemotherapy might unlock the future of triple-negative breast cancer [4].

Understanding how selective pressure from chemotherapy directs the evolution of urothelial carcinoma and shapes, its clonal architecture is crucial [5].

It is particularly significant to view the complex scenario of tumor cell biology as systems of inter-related events that potentiate each other, with the overall aim at restricting metastatic potential of neoplastic cells. Combining cancer vaccine and checkpoint blockade for treating HPV-related cancer is a promising approach [6].

## Network Operabilities

The increments in tumor cell growth, proliferation and spread are paramount considerations as the tumor progresses clinically and pathophysiologically. The identification of molecular markers could early predict the metastatic potential of tumors such as thyroid cancer [7]. The performance strategies of tumor effects are a complex phenomenon in terms of the evolutionary potentials of neoplastic cells in general. Epithelial-mesenchymal transition is a crucial step in cancer progression and plays a key role in tumor metastasis [8]. A network approach is based on the realization of complex interactions that emphasize, in particular, the antigen presentation by professional cells such as dendritic cells. This formulation approach is further significant within scopes of multi-organ spread of neoplasms in general. It is in terms of such network operabilities that the overall clinical dimensions of tumor spread further illustrate the dynamics of growth and spread of tumor cells.

Inclusive phenomena in the performance, in particular, of growth of neoplastic cells, are the weak immunogenicity of tumor cells. The multi-step reprogramming process resulting in a phenotype switch from an epithelial to a mesenchymal cellular state has been closely related to the acquisition of stem cell-like attributes in tumors [9]. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma [10]. The exposure of antigenic epitopes is a central consideration in the performance attempts with the realization of antigen-presenting cells infiltrating the tumor itself. In such terms, interleukin 2 effects are potentiation as expansion performance on such infiltrating tumor lymphocytes. The emergence of such a concept is the complexities of performance of antigen presentation by dendritic cells.

## Dimensions of Epitope Biology

Overall dimensions in the antigen epitope biology are emphasized as central to such tumors as metastatic melanoma. The incremental functionalities of realization are emphasized by the recognition of early phase dynamics as terms of self-potentiating factors in performance agency against the tumor in question. Hence, the importance of early phase tumor cell growth and proliferation is underlined by the essential need to prevent self-potentiation of the tumor biology dynamics. Transforming growth factor-beta induces epithelial-mesenchymal transition in hepatocellular carcinoma and probably also changes in tumor cell plasticity [11].

It is significant to view the essential evolutionary history of a tumor lesion as primarily self-potentiating, even as the neoplastic cells initiate spread very early in the course of growth and proliferation. Tumor-Associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma [12].

## Weak Immunogenicity and Metastases

Profile systems of antigenicity are inherent within the systems of carcinogenicity as projected by the increments of progression of the metastatic potential. In real terms, the ability of neoplastic cells to spread early in the course of carcinogenesis is highly significant, and is in fact suggestive of an intrinsic potentiality of the tumorigenesis that is inherent to the metastatic potential of a given tumor lesion. The synergistic interactions exist between CD44 and transforming growth factor-Beta1 in epithelial mesenchymal transition induction and of cancer stem cell properties through the AKT/GSK-3Beta/Beta-catenin pathway in hepatocellular carcinoma cells [13]. In such terms, it appears significant to consider antigenicity within the central phenomenon of early spread of the tumor cells. Such a concept would lead to a realization of growth and proliferation as epiphenomena of such early metastatic capability and operability of the neoplastic cells, in focused terms.

## Early Spread Potential

Such a concept therefore reverts the question of early spread as an originator of escalating incremental phenomena

of the growth and spread of the tumor cells, inherently operating a poor immunogenicity phenomenon. In such terms, therefore, the weak immunogenicity of tumor cells, both in general and specific terms, operates as a fundamental instigator in the incremental growth and proliferation of the neoplastic cells.

## Concluding Remarks

Systems of profile performance are inherent models of incremental growth and proliferation of tumor cells very early in the acquisition of metastatic spread potential of these cells. It is in terms of overall performance that the increments of tumor spread are translated in as increments of growth and spread of tumor cells as group biology of lesion pathophysiology. The dynamics of incremental growth and proliferation are central to metastatic potential that directly implicates weak immunogenicity of the tumor cells.

## References

1. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1): 58-68.

2. Giannelli G, Koudelkova P, Dituri F, Mikulits W (2016) Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatic 65(4): 798-808.

3. Pende D, Falco M, Vitale M, Cantoni C, Vitale C, et al. (2019) Killer Ig-like receptors (KIRs): Their role in NK cell modulation and developments leading to their clinical exploitation. Front Immune 10: 1179.

4. Park JH, Ahn JH, Kim SB (2018) How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immune-molecular strategies. ESMO Open 3(1): e000357.

5. Faltas BM, Prandi D, Tarawa ST, Molina AM, Nanus DM, et al. (2016) Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet 48(12): 1490-1499.

6. Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M (2019) The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev 78: 8-16.

7. Gugnoni M, Sancisi V, Gandolfi G, Manzotti G, Ragazzi M, et al. (2017) Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy. Oncogene 36(5): 667-677.

8. Da C, Wu K, Yue C, Bai P, Wang R, et al. (2017) N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways. Oncotarget 8(5): 8131–8142.

9. Jayachandran A, Dhungel B, Steel JC (2016) Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol 9(1): 74.

10. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Intonaci S (2005) Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129(5): 1375-1383.

11. Fan QM, Jing YY, Yu GF, Kou XR, Ye F, et al. (2014 ) Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett 352(2): 160-168.

12. Malfettone A, Soukupova J, Bertran E, Crosas-Molist E, Lastra R, et al. (2017) Transforming growth factor-beta-induced plasticity causes a migratory stemless phenotype in hepatocellular carcinoma. Cancer Lett 392: 39-50.

13. Park NR, Cha JH, Jang JW, Bae SH, Jang B, et al. (2016) Synergistic effects of CD44 and TGF-beta1 through AKT/GSK-3beta/beta-catenin singling during epithelial-mesenchymal transition in liver cancer cells. Biochem Biophys Res Commun 477(4): 568-574.